3 Indian Exchange Stocks Estimated To Be Undervalued In July 2024

In This Article:

The Indian stock market has shown robust growth, rising by 2.3% in the last week and an impressive 45% over the past year, with earnings expected to grow by 16% annually. In this thriving market environment, identifying stocks that are potentially undervalued could offer investors a strategic advantage.

Top 10 Undervalued Stocks Based On Cash Flows In India

Name

Current Price

Fair Value (Est)

Discount (Est)

HEG (NSEI:HEG)

₹2111.75

₹3300.29

36%

IOL Chemicals and Pharmaceuticals (BSE:524164)

₹426.60

₹636.71

33%

Updater Services (NSEI:UDS)

₹318.80

₹536.78

40.6%

Venus Pipes and Tubes (NSEI:VENUSPIPES)

₹2211.45

₹3586.71

38.3%

Vedanta (NSEI:VEDL)

₹448.95

₹721.52

37.8%

Rajesh Exports (NSEI:RAJESHEXPO)

₹315.35

₹508.03

37.9%

Mahindra Logistics (NSEI:MAHLOG)

₹530.65

₹855.39

38%

Strides Pharma Science (NSEI:STAR)

₹1030.15

₹1664.05

38.1%

Delhivery (NSEI:DELHIVERY)

₹412.40

₹751.11

45.1%

Godrej Properties (NSEI:GODREJPROP)

₹3129.85

₹5531.73

43.4%

Click here to see the full list of 19 stocks from our Undervalued Indian Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

Delhivery

Overview: Delhivery Limited offers supply chain solutions to a diverse range of industries including e-commerce, FMCG, and automotive in India, with a market capitalization of approximately ₹304.85 billion.

Operations: The revenue from logistics services for the company amounts to ₹81.42 billion.

Estimated Discount To Fair Value: 45.1%

Delhivery, currently valued at ₹412.4, is trading significantly below its fair value estimate of ₹751.11, indicating a potential undervaluation of over 45%. Despite a challenging market, Delhivery has demonstrated robust earnings growth at an annual rate of 16.5% over the past five years and is expected to turn profitable within the next three years with forecasted profit growth outpacing the market. However, its revenue growth projection of 14.3% annually lags behind more aggressive market averages but still exceeds general Indian market expectations. Recent strategic executive appointments and expansions into new business areas like drone logistics suggest operational enhancements that might support future financial performance despite current forecasts showing a low return on equity in three years' time.

NSEI:DELHIVERY Discounted Cash Flow as at Jul 2024
NSEI:DELHIVERY Discounted Cash Flow as at Jul 2024

Piramal Pharma

Overview: Piramal Pharma Limited is a global pharmaceutical company with operations across North America, Europe, Japan, and India, boasting a market capitalization of approximately ₹225.75 billion.